Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Why this trial matters : First oral SERD to succeed in Phase III in early breast cancer Signals a potential new adjuvant standard of care Advances endocrine therapy beyond legacy agents Johnson & Johnson Tecvayli + Darzalex Faspro Shows Unprecedented Phase III Success in Relapsed/Refractory Multiple Myeloma The Phase III MajesTEC-3 trial demonstrated that the combination of Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab SC) significantly improved progression-free survival and overall survival versus standard regimens in patients with relapsed/refractory multiple myeloma as early as second-line, with an ~83% reduction in disease progression or death at almost three years follow-up
Anti-inflammatory diet emphasizing omega-3s, polyphenols, and antioxidants
19, e0012763
Always consult a healthcare professional or the drug manufacturer to ensure compatibility
doi: 10.3390/antiox9111070 51 AtesIArikanMFAltayMYilmazFMYilmazNBerkerDet al
US$ 28.40
US$ 27.32
US$ 27.28
US$ 21.43
US$ 27.17
US$ 23.48
US$ 21.33
US$ 24.43
US$ 23.52
US$ 27.49
US$ 28.63
US$ 26.08
US$ 22.59
US$ 27.60